ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SM..................J0009190-CORR01This application was filed on 02.04.2026 as a divisional application to the application mentioned under INID code 62.Claims filed after the date of filing/ after the date of receipt of the divisional application (Rule 68(4) EPC)4782065CORRECTED EUROPEAN PATENT APPLICATIONA8A220261021W171deBibliographieenBibliographyfrBibliographieEP26170374.82020091120260402enenenPCT/EP2019/07456520190913WO202610212026432026072920263120261021202643A61K 31/506 20060101AFI20260831BHEP A61P 35/00 20060101ALI20260831BHEP A61K 31/506 20130101 LI20200513BHEP A61K2300/00 20130101 LI20200513BHEP A61K 31/506 20130101 FI20200513BHEP A61P 35/00 20180101 LI20200513BHEP deTHERAPEUTISCHE ZUSAMMENSETZUNGEN, KOMBINATIONEN UND VERFAHREN ZUR VERWENDUNGenTHERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USEfrCOMPOSITIONS THÉRAPEUTIQUES, COMBINAISONS ET PROCÉDÉS D'UTILISATION20772249.7402801020200911The Institute of Cancer Research: Royal Cancer Hospital100236311280344_a_lan123 Old Brompton RoadLondon SW7 3RPGBBANERJI, UdaiLondon, SW7 3RPGBHoffmann Eitle100061036Patent- und Rechtsanwälte PartmbB Arabellastraße 3081925 MünchenDEALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTR20261007202641

This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CH5126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.